Advert - Lundbeck – Case AUTH/3550/7/21
Concerns about the promotion of Vyepti at a virtual symposium
- 
                        Date posted12 December 2022
- 
                            SanctionAdvertisement,
- 
                            Case number/s
For promoting a pipeline product at a symposium session, and for that session to be available on demand on a third party website (without the pharmaceutical company’s permission), Lundbeck was ruled in breach of the following clauses of the 2019 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 3.1 - Promoting a medicine prior to its marketing authorisation
Clause 9.1 - Failing to maintain high standards
Clause 9.10 - Failing to be sufficiently clear as to the company’s role and involvement
